Prevalence of CD8+ cytotoxic lymphocytes in human neoplasms

  1. Blessin, Niclas C.
  2. Spriestersbach, Patrick
  3. Li, Wenchao
  4. Mandelkow, Tim
  5. Dum, David
  6. Simon, Ronald ORCID logo
  7. Hube-Magg, Claudia
  8. Lutz, Florian
  9. Viehweger, Florian
  10. Lennartz, Maximillian
  11. Fraune, Christoph
  12. Nickelsen, Vera
  13. Fehrle, Wilfried
  14. Göbel, Cosima
  15. Weidemann, Sören
  16. Clauditz, Till
  17. Lebok, Patrick
  18. Möller, Katharina
  19. Steurer, Stefan
  20. Izbicki, Jacob R.
  21. Sauter, Guido
  22. Minner, Sarah
  23. Jacobsen, Frank
  24. Luebke, Andreas M.
  25. Büscheck, Franziska
  26. Höflmayer, Doris
  27. Wilczak, Waldemar
  28. Burandt, Eike
  29. Hinsch, Andrea

Download
s13402-020-00496-7.pdf 1,73MB
WeightNameValue
1000 Titel
  • Prevalence of CD8+ cytotoxic lymphocytes in human neoplasms
1000 Autor/in
  1. Blessin, Niclas C. |
  2. Spriestersbach, Patrick |
  3. Li, Wenchao |
  4. Mandelkow, Tim |
  5. Dum, David |
  6. Simon, Ronald |
  7. Hube-Magg, Claudia |
  8. Lutz, Florian |
  9. Viehweger, Florian |
  10. Lennartz, Maximillian |
  11. Fraune, Christoph |
  12. Nickelsen, Vera |
  13. Fehrle, Wilfried |
  14. Göbel, Cosima |
  15. Weidemann, Sören |
  16. Clauditz, Till |
  17. Lebok, Patrick |
  18. Möller, Katharina |
  19. Steurer, Stefan |
  20. Izbicki, Jacob R. |
  21. Sauter, Guido |
  22. Minner, Sarah |
  23. Jacobsen, Frank |
  24. Luebke, Andreas M. |
  25. Büscheck, Franziska |
  26. Höflmayer, Doris |
  27. Wilczak, Waldemar |
  28. Burandt, Eike |
  29. Hinsch, Andrea |
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-03-05
1000 Erschienen in
1000 Quellenangabe
  • 43(3):421-430
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s13402-020-00496-7 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214387/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Purpose!#!Immune checkpoint inhibitors have recently been approved by the US FDA as first and/or second line therapy in a subset of cancer types. Recent evidence suggests that the quantity of tumor infiltrating lymphocytes (TILs) influences the likelihood of response to immune checkpoint inhibitors. Here, we set out to assess the density of CD8!##!Methods!#!The density of CD8!##!Results!#!We found that the median CD8!##!Conclusion!#!These data support the concept that among most tumor types at least some individual cancers may benefit from treatment with immune checkpoint inhibitors.
1000 Sacherschließung
lokal Immune checkpoint
lokal Article
lokal Lymphocyte Count [MeSH]
lokal Humans [MeSH]
lokal Neoplasms/immunology [MeSH]
lokal Cytotoxic T cells
lokal Lymphocytic infiltrate
lokal Tissue Array Analysis [MeSH]
lokal Tissue microarray
lokal CD8-Positive T-Lymphocytes/immunology [MeSH]
lokal Lymphocytes, Tumor-Infiltrating/immunology [MeSH]
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/Qmxlc3NpbiwgTmljbGFzIEMu|https://frl.publisso.de/adhoc/uri/U3ByaWVzdGVyc2JhY2gsIFBhdHJpY2s=|https://frl.publisso.de/adhoc/uri/TGksIFdlbmNoYW8=|https://frl.publisso.de/adhoc/uri/TWFuZGVsa293LCBUaW0=|https://frl.publisso.de/adhoc/uri/RHVtLCBEYXZpZA==|https://orcid.org/0000-0003-0158-4258|https://frl.publisso.de/adhoc/uri/SHViZS1NYWdnLCBDbGF1ZGlh|https://frl.publisso.de/adhoc/uri/THV0eiwgRmxvcmlhbg==|https://frl.publisso.de/adhoc/uri/VmllaHdlZ2VyLCBGbG9yaWFu|https://frl.publisso.de/adhoc/uri/TGVubmFydHosIE1heGltaWxsaWFu|https://frl.publisso.de/adhoc/uri/RnJhdW5lLCBDaHJpc3RvcGg=|https://frl.publisso.de/adhoc/uri/Tmlja2Vsc2VuLCBWZXJh|https://frl.publisso.de/adhoc/uri/RmVocmxlLCBXaWxmcmllZA==|https://frl.publisso.de/adhoc/uri/R8O2YmVsLCBDb3NpbWE=|https://frl.publisso.de/adhoc/uri/V2VpZGVtYW5uLCBTw7ZyZW4=|https://frl.publisso.de/adhoc/uri/Q2xhdWRpdHosIFRpbGw=|https://frl.publisso.de/adhoc/uri/TGVib2ssIFBhdHJpY2s=|https://frl.publisso.de/adhoc/uri/TcO2bGxlciwgS2F0aGFyaW5h|https://frl.publisso.de/adhoc/uri/U3RldXJlciwgU3RlZmFu|https://frl.publisso.de/adhoc/uri/SXpiaWNraSwgSmFjb2IgUi4=|https://frl.publisso.de/adhoc/uri/U2F1dGVyLCBHdWlkbw==|https://frl.publisso.de/adhoc/uri/TWlubmVyLCBTYXJhaA==|https://frl.publisso.de/adhoc/uri/SmFjb2JzZW4sIEZyYW5r|https://frl.publisso.de/adhoc/uri/THVlYmtlLCBBbmRyZWFzIE0u|https://frl.publisso.de/adhoc/uri/QsO8c2NoZWNrLCBGcmFuemlza2E=|https://frl.publisso.de/adhoc/uri/SMO2ZmxtYXllciwgRG9yaXM=|https://frl.publisso.de/adhoc/uri/V2lsY3phaywgV2FsZGVtYXI=|https://frl.publisso.de/adhoc/uri/QnVyYW5kdCwgRWlrZQ==|https://frl.publisso.de/adhoc/uri/SGluc2NoLCBBbmRyZWE=
1000 Hinweis
  • DeepGreen-ID: adad15b7fcfb4736a61a7906a02e8bfb ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
  1. Prevalence of CD8+ cytotoxic lymphocytes in human neoplasms
    Prevalence of CD8+ cytotoxic lymphocytes in human neoplasms
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6470874.rdf
1000 Erstellt am 2023-11-18T09:24:38.922+0100
1000 Erstellt von 322
1000 beschreibt frl:6470874
1000 Zuletzt bearbeitet 2023-12-01T13:11:30.903+0100
1000 Objekt bearb. Fri Dec 01 13:11:30 CET 2023
1000 Vgl. frl:6470874
1000 Oai Id
  1. oai:frl.publisso.de:frl:6470874 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source